

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 August 2023 (17.08.2023)



(10) International Publication Number
WO 2023/154896 A2

(51) International Patent Classification:

A61K 47/55 (2017.01) C07D 311/04 (2006.01)

(21) International Application Number:

PCT/US2023/062436

(22) International Filing Date:

10 February 2023 (10.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/309,337	11 February 2022 (11.02.2022)	US
63/327,342	04 April 2022 (04.04.2022)	US
63/335,150	26 April 2022 (26.04.2022)	US
63/352,809	16 June 2022 (16.06.2022)	US

(71) Applicant: ADARX PHARMACEUTICALS, INC.

[US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors: CHIRUTA, Chandramouli; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). HUANG, Huey-jing; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). LI, Zhen; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). ZHU, Rui; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). AZIMIOARA, Mihai; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). CHENG, Bo; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(74) Agent: HSI, Jeffrey, D. et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

(54) Title: TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF

(57) Abstract: Provided herein are TrkB ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using said compounds.

WO 2023/154896 A2